Raymond James Financial
BCTX

Raymond James Financial’s Briacell Therapeutics BCTX Stock Holding History

Raymond James Financial’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$300 – 5137
2025
Q2 		$300 Buy
+10
New +$365 ﹤0.01% 6738

Other funds holding BCTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Raymond James Financial's BCTX Position: Q3 2025 in Review

Raymond James Financial sold out of Briacell Therapeutics (BCTX) in Q3 2025, closing a stake of 10 shares — an estimated $300 sold.

Raymond James Financial first reported a position in BCTX in Q2 2025 and held it in 1 quarter. The position peaked at $300 in Q2 2025. 13 funds tracked by Wall St. Rank hold BCTX as of Q3 2025.

  • Raymond James Financial reported no remaining Briacell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 10 Briacell Therapeutics shares in Q3 2025, an estimated $300.
  • Raymond James Financial first reported a position in Briacell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Briacell Therapeutics position peaked at $300 in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.